Coffee and Liver Health: What the Science Says

Last updated: June 2026

How coffee may act on the liver

Coffee is more than a dose of caffeine: it is a mixture of more than a thousand compounds, several of which matter for the liver. The most studied are the chlorogenic acids, a family of antioxidant polyphenols. In laboratory work they reduce fat accumulation in liver cells, improve insulin sensitivity and dampen the signalling pathways that drive fibrosis, partly by acting on the growth factor TGF-beta.

Caffeine itself probably contributes too. It modulates adenosine receptors involved in activating hepatic stellate cells, the cells that lay down the scar tissue of fibrosis. That may explain why decaffeinated coffee, though beneficial in some studies, sometimes appears slightly less protective than caffeinated coffee.

Then there are the diterpenes, cafestol and kahweol, carried in coffee's oily fraction. Depending on how the coffee is brewed, they can instead raise cholesterol and, at high intake, some liver markers. That is why distinguishing filtered from unfiltered coffee, covered below, is worth the trouble.

Fibrosis and cirrhosis: the best-documented link

Fibrosis is the build-up of scar tissue in the liver; at its extreme it becomes cirrhosis. This is where the coffee evidence is strongest. A meta-analysis by Kennedy and colleagues, published in Alimentary Pharmacology and Therapeutics in 2016, pooled nine studies and estimated that each extra cup per day was associated with roughly a 22 per cent lower risk of cirrhosis (a relative risk near 0.78).

A separate meta-analysis in PLOS One in 2015 compared coffee drinkers with non-drinkers: cirrhosis risk was about 39 per cent lower among drinkers, and advanced fibrosis about 27 per cent lower. The effect held in both alcohol-related liver disease and chronic hepatitis C. These remain observational findings: they show a strong link but do not, on their own, prove that coffee is the direct cause.

Fatty liver (NAFLD): a promising signal

Non-alcoholic fatty liver disease, or NAFLD, is fat accumulation in the liver of people who drink little or no alcohol. It has become the most common chronic liver disease in Western countries, tied to excess weight and metabolic syndrome.

Several reviews suggest coffee plays a protective role. A 2021 systematic review with meta-analysis linked regular coffee intake to roughly a 30 per cent lower risk of NAFLD and about 35 per cent lower odds of significant fibrosis among those already affected. The proposed mechanism is consistent: chlorogenic acids improve glucose metabolism and limit lipid storage in the liver. Even so, coffee accompanies rather than replaces weight loss and physical activity, which remain the cornerstones of management.

Liver cancer: a recognised protective signal

Hepatocellular carcinoma is the most common primary liver cancer. It is one of the few cancers for which the literature attributes a consistent protective effect to coffee. Cohort and case-control studies, and their meta-analyses, place the risk reduction at 35 to 50 per cent among regular drinkers compared with non-drinkers.

This weighed on a major decision: in June 2016 the International Agency for Research on Cancer (IARC), the WHO's cancer arm, moved coffee from Group 2B ("possibly carcinogenic") to Group 3 ("not classifiable as to its carcinogenicity"). After reviewing more than a thousand studies it found no evidence that coffee causes cancer, and explicitly noted reduced risk for cancers of the liver and the endometrium.

Liver enzymes (ALT, GGT): often lower

ALT (alanine aminotransferase) and GGT (gamma-glutamyl transferase) are enzymes measured in blood to gauge liver health: raised levels often signal liver stress. In several large population studies, regular coffee drinkers show on average lower ALT and GGT than non-drinkers, including among people at risk through alcohol, excess weight or viral hepatitis.

A controlled trial in NAFLD patients found a significant drop in ALT and AST after a supplement combining caffeine and chlorogenic acid, which strengthens the biological coherence of the observational data. One caveat: at very high intakes of unfiltered, diterpene-rich coffee, ALT may instead rise slightly, which returns us to the question of brewing.

Filtered or unfiltered coffee: the nuance that matters

For the liver as an organ, filtered and unfiltered coffee are both linked to favourable effects. The difference lies elsewhere, in cholesterol. Unfiltered coffee (French press, Scandinavian boiled coffee, Turkish coffee and, to a lesser extent, espresso) contains diterpenes, cafestol and kahweol, up to about thirty times more concentrated than in paper-filtered coffee.

These diterpenes raise LDL cholesterol and triglycerides, and can modestly raise ALT at high intake. A paper filter retains most of them. In practice: if your lipid profile is being monitored, favouring filtered coffee is sensible; for the liver benefit alone, the brewing method matters less than how regularly you drink it.

How many cups a day?

In the literature the liver benefit mainly appears from two cups a day, with a dose-response that often strengthens up to three or four cups. Beyond that, the extra gain flattens out. The European Food Safety Authority (EFSA) considers caffeine intakes up to 400 mg per day for healthy adults, roughly four to five cups, to raise no safety concern; the limit drops to 200 mg per day during pregnancy.

In other words, there is no point forcing the dose: piling on cups beyond four brings no known extra liver benefit and may disrupt sleep or blood pressure. One key point: added sugar, syrups and cream can cancel out the metabolic upside. Black coffee, or very lightly sweetened, is the form the studies looked at.

Frequently asked questions

Sources

• IARC / WHO, Monographs Volume 116, evaluation of coffee drinking (reclassified to Group 3, June 2016).
• Kennedy O.J. et al., coffee and hepatocellular carcinoma, and the cirrhosis meta-analysis, Alimentary Pharmacology and Therapeutics, 2016.
• Liu F. et al., "Coffee Consumption Decreases Risks for Hepatic Fibrosis and Cirrhosis: A Meta-Analysis", PLOS One, 2015.
• Systematic review with meta-analysis on coffee and NAFLD / significant fibrosis, 2021.
• EFSA, Scientific Opinion on the safety of caffeine, 2015 (400 mg/day threshold for adults).
• Studies on coffee diterpenes (cafestol, kahweol) in unfiltered coffee and their effects on blood lipids and ALT, Wageningen University.